About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 436 record(s)
Req # A-2021-001200
Adverse Drug Reactions (ADRs) for Finasteride. Report numbers: 571899, 941688, E2B_03301156, E2B_03380752, E2B_03771223, 735573. ADRs for Losartan/HCTZ. Report numbers: 918250, 935424, E2B_03703533, E2B_03847999, E2B_03454026. ADRs for Olopatadine. Report numbers: E2B_01709289, E2B_03291404, E2B_03443945, E2B_03665803, E2B_04078743.Organization: Health Canada
October 2022
Req # A-2021-001711
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-119343-495.Organization: Health Canada
October 2022
Req # A-2021-002119
Adverse Drug Reactions (ADRs) for DEXILANT. Report numbers: E2B_04943797, E2B_04880991, 000976370. ADRs for ENTYVIO. Report numbers: 000977179, E2B_04880977, E2B_04870016. ADR for IXAZOMIB. Report number: E2B_04948559. ADRs for ONDANSETRON. Report numbers: 000976212, 000975700. ADRs for PANTOPRAZOLE SODIUM. Report numbers: E2B_04892483, E2B_04931140, E2B_04925605, E2B_04925508, E2B_04869537, E2B_04905619, E2B_04938853. ADR for ADDERALL XR. Report number: 000975227. ADR for AMPHETAMINE ASPARTATE MONOHYDRATE/ AMPHETAMINE SULFATE/ DEXTROAMPHETAMINE SACCHARATE/ DEXTROAMPHETAMINE SULFATE. Report number: E2B_04892820.Organization: Health Canada
October 2022
Req # A-2021-002124
Adverse Drug Reactions (ADRs) for ALEMTUZUMAB, ASRILUMAB, INSULIN GLARGINE. Report numbers: 969401, 972998, E2B_04847683, 974026, E2B_04760111, E2B_02204747, E2B_04701960, E2B_04728917.Organization: Health Canada
October 2022
Req # A-2021-002126
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-100917-441, COVID-19 Test Requirements in Northern, Remote and Isolated Communities.Organization: Health Canada
October 2022
Req # A-2022-000059
Adverse Drug Reactions (ADRs) for Ondansetron. Report numbers: E2B_05025498, E2B_04997253, 000982344. ADRs for Pantoprazole sodium. Report numbers: E2B_04987689, E2B_05023248, E2B_05042650, E2B_05078451, E2B_05002477, E2B_04988447, E2B_05059051.Organization: Health Canada
October 2022
Req # A-2022-000097
Adverse Drug Reactions (ADRs) for ALEMTUZUMAB. Report numbers: E2B_05036607, E2B_05042570.Organization: Health Canada
October 2022
Req # A-2022-000124
Adverse Drug Reactions (ADRs). Report numbers: E2B_05046689, E2B_05047199 , E2B_05040991, E2B_05045866, E2B_05046386, E2B_05032965, E2B_05027426, E2B_05045924, E2B_05047237 E2B_05047153.Organization: Health Canada
October 2022
Req # A-2022-000135
Adverse Drug Reactions (ADRs). Report numbers: E2B_05023126, E2B_05041323, E2B_05020394, E2B_05027401, E2B_05046752, E2B_05047020, E2B_05041464, E2B_05046181, E2B_05041412, E2B_05046433.Organization: Health Canada
October 2022
Req # A-2022-000225
Adverse Drug Reactions (ADRs). Report numbers: E2B_04968642, E2B_04943076, E2B_04954829, E2B_04954821, E2B_04960737, E2B_04972409, E2B_04972379, E2B_04972477, 978332, E2B_04983059.Organization: Health Canada
October 2022